Advanced search
Publication Cover
Hematology Volume 28, 2023 - Issue 1
Submit an article Journal homepage
543
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Industry’s role in HIV, hepatitis B, and hepatitis C exclusion in AML and MDS clinical trials

Tahsin Anwara Augusta University, Augusta, GeorgiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3160-802X
ORCID Icon,
Sean Malhotrab Emory University, Atlanta, Georgia
,
Mohammad A. H. Mianc Augusta University Medical Center, Augusta, Georgia;d Georgia Cancer Center, Augusta University, Augusta, Georgia
,
Tahiya Anwarc Augusta University Medical Center, Augusta, Georgia
,
Vamsi Kotaa Augusta University, Augusta, Georgia;c Augusta University Medical Center, Augusta, Georgia;d Georgia Cancer Center, Augusta University, Augusta, Georgia;e Medical College of Georgia, Augusta University, Augusta, Georgia
&
Mahran Shoukiere Medical College of Georgia, Augusta University, Augusta, Georgia
Article: 2254558 | Published online: 07 Sep 2023

References

  • Bayh-Dole Act. 1980: United States of America. p. 3018.
  • Okike K, Kocher MS, Mehlman CT, et al. Industry-sponsored research. Injury. 2008;39(6):666–680. doi: 10.1016/j.injury.2008.02.013
  • Chopra SS. Industry funding of clinical trials: benefit or bias? JAMA. 2003;290(1):113–114. doi: 10.1001/jama.290.1.113
  • Lièvre M, Ménard J, Bruckert E, et al. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility commentary: early discontinuation violates Helsinki principles. BMJ. 2001;322(7286):603–606. doi: 10.1136/bmj.322.7286.603
  • Psaty BM, Rennie D. Stopping medical research to save money: a broken pact with researchers and patients. JAMA. 2003;289(16):2128–2131.
  • Patino CM, Ferreira JC. Inclusion and exclusion criteria in research studies: definitions and why they matter. J Bras Pneumol. 2018;44(2):84.
  • Kim ES, Bruinooge SS, Roberts S, et al. Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint research statement. J Clin Oncol. 2017;35(33):3737. doi: 10.1200/JCO.2017.73.7916
  • National Research Council. The prevention and treatment of missing data in clinical trials. Washington (DC): National Academies Press; 2010.
  • Torres HA, Shigle TL, Hammoudi N, et al. The oncologic burden of hepatitis C virus infection: a clinical perspective. CA Cancer J Clin. 2017;67(5):411–431.
  • Jin S, Pazdur R, Sridhara R. Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015. J Clin Oncol. 2017;35(33):3745–3752. doi: 10.1200/JCO.2017.73.4186
  • Torres HA, Pundhir P, Mallet V. Hepatitis C virus infection in patients with cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 2019;157(4):909–916. doi: 10.1053/j.gastro.2019.01.271
  • Bakouny Z, Labaki C, Bhalla S, et al. Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study. Ann Oncol. 2022;33(8):836–844. doi: 10.1016/j.annonc.2022.04.071
  • Negri F, Missale G, Antoni AD, et al. Hepatocellular cancer therapy in patients with HIV infection: disparities in cancer care, trials enrolment, and cancer-related research. Transl Oncol. 2021;14(9):101153. doi: 10.1016/j.tranon.2021.101153
  • Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. doi: 10.1371/journal.pone.0081355
  • Lewden C, Bouteloup V, De Wit S, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥ 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41(2):433–445. doi: 10.1093/ije/dyr164
  • Mahy MI, Sabin KM, Feizzadeh A, et al. Progress towards 2020 global HIV impact and treatment targets. J Int AIDS Soc. 2021;24:e25779. doi: 10.1002/jia2.25779
  • Zhang X, Direct anti-HCV agents. Acta Pharm Sin B. 2016;6(1):26–31. doi: 10.1016/j.apsb.2015.09.008

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.